Pilot study: Evaluation of ease-of-use of Acapsil as first-line treatment for active Hidradenitis Suppurativa lesions

We, Willingsford, are recruiting volunteers with active HS lesions. The aim of the evaluation is to optimise the ease-of-use of Acapsil as first-line treatment of active Hidradenitis Suppurativa lesions without sinus tracts.   Purpose The overall purpose of the study is to determine how to optimally use Acapsil (micropore-particle-technology) as first-line treatment of active lesions in Hidradenitis…

Continue Reading Pilot study: Evaluation of ease-of-use of Acapsil as first-line treatment for active Hidradenitis Suppurativa lesions
Chair of the WHO Antimicrobial Resistance (AMR) group

Publication shows that MPPT acts as a passive immunotherapy that interacts with the microbiome and calls for a paradigm shift in the treatment of wounds and ulcers (Sams-Dodd et al. 2018). In response to these findings, Executive Board member of the World Health Organization (WHO), and chair of the WHO Strategic and Technical Advisory Group on Anti-Microbial-Resistance,…

Continue Reading Chair of the WHO Antimicrobial Resistance (AMR) group